MedTrace Logo

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

NCT07240116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-13

No results posted yet for this study

Summary

This single-center, randomized, open-label study will assess the relative bioavailability of 2 miricorilant (CORT118335) tablet formulations.

Conditions

  • Healthy

Interventions

DRUG

Miricorilant Treatment A

Miricorilant 100 mg (1 x 100 mg) Kinetisol immediate release (IR) tablet for oral administration

DRUG

Miricorilant Treatment B

Miricorilant 100 mg (2 x 50 mg) Kinetisol IR tablet for oral administration

DRUG

Miricorilant Treatment C

Miricorilant 100 mg (2 x 50 mg) SDD IR tablet for oral administration

DRUG

Miricorilant Treatment D

Miricorilant 100 mg (1 x 100 mg or 2 x 50 mg) Kinetisol IR tablet for oral administration. The tablet strength administered will be decided after Period 3 is complete.

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Joseph Custodio, PhD · Corcept Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-11
Primary Completion
2026-03-03
Completion
2026-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240116 on ClinicalTrials.gov